Search

Search Constraints

You searched for: Author/Creator Mori, Nami

Search Results

1. A validation study of after direct‐acting antivirals recommendation for surveillance score for the development of hepatocellular carcinoma in patients with hepatitis C virus infection who had received direct‐acting antiviral therapy and achieved sustained virological response. Issue 1 (8th December 2021)

2. Change in Fibrosis 4 Index as Predictor of High Risk of Incident Hepatocellular Carcinoma After Eradication of Hepatitis C Virus. (5th February 2021)

3. Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status. Issue 10 (10th May 2018)

4. Emergence of drug resistance‐associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir‐treated chronic hepatitis C patients. Issue 11 (25th July 2017)

5. General evaluation score for predicting the development of hepatocellular carcinoma in patients with advanced liver fibrosis associated with hepatitis C virus genotype 1 or 2 after direct‐acting antiviral therapy. Issue 7 (8th June 2022)

6. Hepatocellular Carcinoma Risk Assessment for Patients With Advanced Fibrosis After Eradication of Hepatitis C Virus. Issue 3 (22nd October 2021)

7. IFNL4 polymorphism effects on outcome of simeprevir, peginterferon, and ribavirin therapy for older patients with genotype 1 chronic hepatitis C. Issue 3 (21st April 2016)

8. Real‐world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1‐ and 2‐infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group. Issue 11 (3rd July 2021)

9. Real‐world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus‐infected cirrhosis patients. Issue 3 (March 2017)

10. Real‐world efficacy of sofosbuvir plus velpatasvir therapy for patients with hepatitis C virus‐related decompensated cirrhosis. Issue 11 (11th September 2020)